ArticleThe American journal of surgical pathology2020
Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
Article in The American journal of surgical pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Pooled it
- Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.Genes · 2022Pooled it
- Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis.Virchows Archiv : an international journal of pathology · 2021Pooled it
- Diagnostic and Prognostic Values of PRAME Immunohistochemistry in Acral Lentiginous Melanoma.The American Journal of dermatopathology · 2026Article
- PRAME immunohistochemistry demonstrates high diagnostic accuracy for distinguishing melanoma from nevi but no observed association with pT stage in cutaneous melanoma: a Vietnamese clinicopathological study.Diagnostic pathology · 2026Article
- [Immunohistochemistry of melanocytic tumours].Pathologie (Heidelberg, Germany) · 2026Review
- Article
- Therapeutic Opportunities in Melanoma Through PRAME Expression.Biomedicines · 2025Review
- Green Synthesis and Characterization of Silver Nanoparticles UsingInternational journal of molecular sciences · 2025Article
- Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma.Cancers · 2025Review
- PRAME Expression in Melanoma is Negatively Regulated by TET2-Mediated DNA Hydroxymethylation.Laboratory investigation; a journal of technical methods and pathology · 2025Article
- Article
- Circulating MicroRNAs: functional biomarkers for melanoma prognosis and treatment.Molecular cancer · 2025Review
- Review
- A Narrative Review of the Evolution of Diagnostic Techniques and Treatment Strategies for Acral Lentiginous Melanoma.International journal of molecular sciences · 2024Review
- PRAME Immunohistochemistry in Thin Melanomas Compared to Melanocytic Nevi.Diagnostics (Basel, Switzerland) · 2024Article
- PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation.bioRxiv : the preprint server for biology · 2024Article
- Shedding light on PRAME expression in dysplastic nevi: a cohort study.Virchows Archiv : an international journal of pathology · 2024Article
- Expression of Preferentially Expressed Antigen in Melanoma, a Cancer/Testis Antigen, in Carcinoma In Situ of the Urinary Tract.Diagnostics (Basel, Switzerland) · 2023Article
- Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.Virchows Archiv : an international journal of pathology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen. Although diffuse immunoreactivity for PRAME is found in most primary cutaneous melanomas, melanocytic nevi express PRAME usually only in a subpopulation of tumor cells or not at all. Hence, testing for PRAME expression has the potential to provide useful information for the assessment for diagnostically ambiguous melanocytic neoplasms. Many of the latter tumors are currently studied by cytogenetic methods for ancillary evidence in support of or against a diagnosis of melanoma. In this study we analyzed 110 diagnostically problematic melanocytic tumors comparing results for PRAME immunohistochemistry (IHC) with those from fluorescence in situ hybridization and/or single nucleotide polymorphism-array, and each with the final diagnostic interpretation. In 90% of cases there was concordance between PRAME IHC and cytogenetic tests results, and in 92.7% concordance between PRAME IHC and the final diagnosis. The high concordance between PRAME IHC and cytogenetic test results as well as the final diagnosis supports the use of PRAME IHC as an ancillary test in the evaluation of ambiguous primary cutaneous melanocytic neoplasms, especially given its practical advantage of lower cost and faster turnaround over cytogenetic or gene expression studies. However, our results indicate that PRAME IHC and cytogenetic tests for melanocytic tumors are not entirely interchangeable and on occasion each type of test may yield false-negative or false-positive results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.